HN2002000366A - Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma - Google Patents

Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma

Info

Publication number
HN2002000366A
HN2002000366A HN2002000366A HN2002000366A HN2002000366A HN 2002000366 A HN2002000366 A HN 2002000366A HN 2002000366 A HN2002000366 A HN 2002000366A HN 2002000366 A HN2002000366 A HN 2002000366A HN 2002000366 A HN2002000366 A HN 2002000366A
Authority
HN
Honduras
Prior art keywords
asthma
activity
treatment
cell factor
precursor cell
Prior art date
Application number
HN2002000366A
Other languages
English (en)
Inventor
Toshihiko Takeuchi
Adrian Tomkinson
Steven Neben
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of HN2002000366A publication Critical patent/HN2002000366A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCION PROVEE DE ANTICUERPOS HUMANOS ESPECIFICOS PARA EL FACTOR DE LAS CELULAS PRECURSORAS QUE CONTIENEN POR LO MENOS UNA CDR DERIVADA DE UNA BIBLIOTECA COMBINATORIA DE ANTICUERPOS.
HN2002000366A 2001-12-17 2002-12-16 Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma HN2002000366A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34217401P 2001-12-17 2001-12-17

Publications (1)

Publication Number Publication Date
HN2002000366A true HN2002000366A (es) 2003-04-21

Family

ID=23340685

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2002000366A HN2002000366A (es) 2001-12-17 2002-12-16 Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma

Country Status (8)

Country Link
US (2) US7285640B2 (es)
AR (1) AR037756A1 (es)
AU (1) AU2002361720A1 (es)
GT (1) GT200200279A (es)
HN (1) HN2002000366A (es)
TW (1) TW200305435A (es)
UY (1) UY27583A1 (es)
WO (1) WO2003051311A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
WO2006002064A2 (en) * 2004-06-14 2006-01-05 Aerovance, Inc. Antibody inhibiting stem cell factor activity and use for treatment of asthma
TW200902555A (en) * 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
EP1957531B1 (en) * 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
DK2158315T3 (en) * 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009135001A2 (en) * 2008-04-30 2009-11-05 University Of Pittsburgh- Commonwealth System Of Higher Education Methods and compositions for regulating th2 and th17 responses
US20100124764A1 (en) * 2008-09-26 2010-05-20 Wyeth Single chain antibody library design
JP2014505057A (ja) * 2011-01-10 2014-02-27 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン 幹細胞因子阻害剤
KR101384360B1 (ko) * 2012-05-04 2014-04-14 아주대학교산학협력단 Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
KR20230066647A (ko) 2016-06-17 2023-05-16 마젠타 테라퓨틱스 인코포레이티드 Cd117+ 세포의 고갈을 위한 조성물 및 방법
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
PT4031569T (pt) * 2019-09-16 2025-11-12 Opsidio Llc Anticorpos anti-fator de células estaminais e seus métodos de utilização

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6187559B1 (en) * 1997-08-28 2001-02-13 Novartis Ag Phospholipase D gene
US6576812B1 (en) * 1999-05-06 2003-06-10 The Trustees Of Columbia University In The City Of New York Compound screening assays using a transgenic mouse model of human skin diseases
JP2003534804A (ja) * 2000-05-30 2003-11-25 アイシーエイチ プロダクションズ リミテッド トランスフェクションの改良方法
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.

Also Published As

Publication number Publication date
AR037756A1 (es) 2004-12-01
WO2003051311A2 (en) 2003-06-26
AU2002361720A8 (en) 2003-06-30
AU2002361720A1 (en) 2003-06-30
TW200305435A (en) 2003-11-01
US20030194405A1 (en) 2003-10-16
US20050112698A1 (en) 2005-05-26
GT200200279A (es) 2003-07-18
WO2003051311A3 (en) 2004-09-30
US7285640B2 (en) 2007-10-23
UY27583A1 (es) 2003-06-30

Similar Documents

Publication Publication Date Title
HN2002000366A (es) Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
ECSP045491A (es) Nueva sal formiato de o-desmetil venlafaxina
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
DE60239931D1 (de) Kombinationstherapie
BRPI0312649A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
EA200501586A1 (ru) Фармацевтические продукты
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
DE69905170T2 (de) Thiazolopyrimidinderivate
HRP20080564T3 (hr) Dihidrotetrabenazini i farmaceutski pripravci koji ih sadrže
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
BRPI0415779A (pt) tratamento de doenças proliferativas usando um oligÈmero antisenso iap e um agente quimioterápico
DK1313462T3 (da) Anvendelse af asiatisk syre eller asiaticosid til behandling af cancer
ECSP078057A (es) Formulaciones de estrógenos conjugados y bazedoxifeno
BR0114903A (pt) 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
ECSP077220A (es) Tratamiento de infecciones bacterianas
BR0314716A (pt) Anticorpos de subunidade alfa de lfa-1 e métodos de uso
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
BRPI0507157A (pt) uso de fator viia ou de um equivalente de fator viia, kit de partes para tratamento de trauma, e, métodos para tratar trauma e para prevenir, tratar trauma
MXPA05009718A (es) Uso de un fibrato y orlistato para el tratamiento de obesidad.
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
NO20071096L (no) Diarylmetylpiperazinderivater, fremstillinger derav og anvendelser derav
ATE471375T1 (de) Vglut-spezifische dsrna-verbindungen